This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Investigations:

  • full blood count - to exclude anaemia
  • platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen level - to exclude DIC
  • chest x-ray - to exclude trophoblastic emboli in lungs
  • electrocardiogram - if tachycardic or over 40 years

Immediately:

  • cross-match blood
  • arrange for an evacuation of the uterus under general anaesthesia

Initial treatment:

  • suction evacuation with sharp curettage of uterus; i.v. oxytocin to reduce blood loss
  • arrange for weekly monitoring of beta-hCG to detect recurrence - necessitates radioimmunoassay as titres may fall to a very low level
  • chemotherapy may be indicated if metastasis detected - usually methotrexate or actinomycin-D
  • there is rarely an indication for hysterectomy

Longer term management:

  • register with the tumour registry
  • monitor beta-hCG 2-4 weekly for the next 1-2 years
  • avoid pregnancy until beta-HCG levels have returned to normal for a period. Advice varies as to for what period of time normal levels should have been recorded before a further pregnancy. Some centres suggest 1-2 years of normal levels before pregnancy
  • avoid using the contraceptive pill until beta-hCG is undetectable as it delays tumour regression
  • advise patient that long term childbearing is not precluded

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.